Rollins receives $6 million grant from Gilead’s HIV initiative
Emory’s Rollins School of Public Health has announced a $6 million grant from Gilead Sciences, Inc. over three years to continue to build the capacity of organizations working on the frontlines of the HIV crisis in communities across the Southern United States.
Emory will serve as one of four Gilead COMPASS coordinating centers alongside the Southern AIDS Coalition, the University of Houston Graduate College of Social Work, and Wake Forest School of Divinity to provide direct support to local community organizations to help mitigate the HIV epidemic in the South.
This is part of a second wave of funding from Gilead, manufacturer of antiretroviral therapies for HIV/AIDS. Emory’s COMPASS coordinating center has directly distributed more than $4.3 million to 104 community organizations, and is directed by Neena Smith-Bankhead, director of capacity building and community engagement. More information here.
In African Americans, the genetic risk landscape for inflammatory bowel disease is very different from that of people with European ancestry, according to new findings.
These results of the first whole-genome study of inflammatory bowel disease (IBD) in African Americans show that future clinical research on IBD needs to take ancestry into account, say the researchers.
Findings of the multi-center study, which analyzed the whole genomes of more than 1,700 affected individuals with Crohn’s disease and ulcerative colitis and more than 1,600 controls, appear in the
As part of their analysis, the researchers developed an algorithm that corrects for ancestry when calculating an IBD polygenic risk score. Polygenic risk scores are tools for calculating gene-based risk for a disease, which are used for IBD as well as other complex conditions such as coronary artery disease.
E-Mail
In African Americans, the genetic risk landscape for inflammatory bowel disease (IBD) is very different from that of people with European ancestry, according to results of the first whole-genome study of IBD in African Americans. The authors say that future clinical research on IBD needs to take ancestry into account.
Findings of the multi-center study, which analyzed the whole genomes of more than 1,700 affected individuals with Crohn s disease and ulcerative colitis and more than 1,600 controls, were published on February 17 in the
American Journal of Human Genetics.
As part of their analysis, the researchers developed an algorithm that corrects for ancestry when calculating an IBD polygenic risk score. Polygenic risk scores are tools for calculating gene-based risk for a disease, which are used for IBD as well as other complex conditions such as coronary artery disease.